Abstract:ID 92341 Poster Board 545 As one of the most successful set of targets for therapeutic development, GPCRs are activated by diverse array of ligands to induce signaling through multiple distinct pathways, yielding varied biological and physiological responses.The pharmacological concept of biased signaling (functional selectivity) describes the ability of select ligands to preferentially activate one receptor-mediated signaling pathway over others. The development of functionally selective ligands holds significant implications for the development of drugs with fewer side effects. Antibodies (Abs) are useful tools for targeting cell surface proteins; however, developing signaling competent GPCR-targeted Abs remains challenging and is often unsuccessful. Camelid single domain antibodies (or nanobodies, Nbs) have been shown to target epitopes in GPCRs not accessible to conventional Abs. However, it remains difficult to identify Nbs that can directly activate GPCR signaling. We developed a unique methodology in our lab to link PTHR1-binding Nbs with synthetic ligands to provide semi-synthetic conjugates that directly modulate GPCR function to overcome this hurdle. Nb-ligand conjugates were prepared through a combination of enzymatic protein labeling, solid-phase peptide (ligand) synthesis, and chemoselective conjugation chemistry. Unlike conventional approaches that modify the core ligand structure, our strategy involves conjugating the ligand to a nanobody that tethers it to the targeted receptor. The activity of Nb-ligand conjugates were assessed in a series of pharmacological assay, including cAMP production, G-protein dissociation, and β-arrestin translocation assays. The linkage of a weakly active PTHR1 ligand fragment (PTH 1-11 ) to a Nb that bound to PTHR1 extracellular domain caused a substantial enhancement in potency for signaling through the G αs pathway. We also assessed duration of signaling in a cAMP "washout" assay. Results revealed that Nb-peptide conjugates induced prolonged cAMP responses upon ligand washout relative to an analogue of a human PTHR1 drug PTH 1-11 . In contrast, these conjugates displayed a drastically impaired capacity to induce recruitment of β-arrestin to the plasma membrane or to early endosomes or to signal via G αq. These findings mark the Nb-PTH 1-11 conjugates as the most biased agonist of PTHR1 reported to date. We also performed mechanistic studies of the origin of bias, revealing that the Nb-PTH 1-11 conjugates can activate signaling through a mode that involves two receptor protomers (activation in trans ). This mechanism is qualitatively distinct from that of conventional PTHR1 ligands such as PTH 1-34 or PTH 1-11 . The platform described here has the potential to advance our understanding of diseases associated with PTHR1 by enabling selective modulation of individual signaling pathways. Work is underway to expand this platform to generate Nb-based biased agonists of other GPCRs including opioid receptors. Facile generation of biased agonists offers the prospect of probing the utility of pathway-selective signaling for the treatment GPCR-associated diseases. This research was supported by the Intramural Research Program of the NIH, The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Calcium-dependent Ligand Binding and G-protein Signaling of Family B GPCR Parathyroid Hormone 1 Receptor Purified in Nanodiscs.

Structure and Dynamics of the Active Human Parathyroid Hormone Receptor-1.

Unraveling the Interplay of Extracellular Domain Conformational Changes and Parathyroid Hormone Type 1 Receptor Activation in Class B1 G Protein-Coupled Receptors: Integrating Enhanced Sampling Molecular Dynamics Simulations and Markov State Models

Structural Basis of Activation and Sustained Signaling by the PTH Receptor

Distinct Conformations of GPCR–β-arrestin Complexes Mediate Desensitization, Signaling, and Endocytosis

Phase-plate Cryo-Em Structure of a Class B GPCR–G-protein Complex

Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation.

Precise druggability of the PTH type 1 receptor

Molecular recognition of two endogenous hormones by the human parathyroid hormone receptor-1

Conserved class B GPCR activation by a biased intracellular agonist

Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission

Nanobody Tethering Enables Highly Biased Agonism for GPCR Ligands

Extracellular domain of human calcium sensing receptor immobilized to silica beads as biomaterial: A rapid chromatographic method for recognizing ligands from complex matrix 'Shuangdan'

[Single-Particle Cryo-Electron Microscopy Opens New Avenues in Structural Biology of G Protein-Coupled Receptor].

Receptor Activity-modifying Protein-directed G Protein Signaling Specificity for the Calcitonin Gene-related Peptide Family of Receptors

Molecular insights into the distinct signaling duration for the peptide-induced PTH1R activation

Two-Dimensional NMR Spectroscopy of the G Protein-Coupled Receptor A2AAR in Lipid Nanodiscs

Direct Determination of Multiple Ligand Interactions with the Extracellular Domain of the Calcium-sensing Receptor*

A Native PAGE Assay for the Biochemical Characterization of G Protein Coupling to GPCRs

Endosomal signaling via cAMP in parathyroid hormone (PTH) type 1 receptor biology

Molecular insights into differentiated ligand recognition of the human parathyroid hormone receptor 2